Here’s every major biotech event for the rest of the year
Biogen’s date with the FDA, Cytokinetics’ shot at a comeback, and Amgen’s chance to shake up oncology are still to come in what has already been an unprecedented year for biotech.
As STAT’s Adam Feuerstein reports, the fourth quarter of 2020 is loaded with events that could change narratives around the industry. Beyond Biogen’s well-covered FDA panel on the Alzheimer’s disease treatment aducanumab, Amgen will have pivotal data on a cancer target once thought to be undruggable, and Cytokinetics will finally disclose the results of a massive study focused on heart failure.
There will also be news from Vertex Pharmaceuticals, Intercept Pharmaceuticals, and, of course, the many companies developing vaccines and therapies for Covid-19.
Read more.
As STAT’s Adam Feuerstein reports, the fourth quarter of 2020 is loaded with events that could change narratives around the industry. Beyond Biogen’s well-covered FDA panel on the Alzheimer’s disease treatment aducanumab, Amgen will have pivotal data on a cancer target once thought to be undruggable, and Cytokinetics will finally disclose the results of a massive study focused on heart failure.
There will also be news from Vertex Pharmaceuticals, Intercept Pharmaceuticals, and, of course, the many companies developing vaccines and therapies for Covid-19.
Read more.
Here’s every major biotech event for the rest of the year
Biogen’s date with the FDA, Cytokinetics’ shot at a comeback, and Amgen’s chance to shake up oncology are still to come in what has already been an unprecedented year for biotech.
As STAT’s Adam Feuerstein reports, the fourth quarter of 2020 is loaded with events that could change narratives around the industry. Beyond Biogen’s well-covered FDA panel on the Alzheimer’s disease treatment aducanumab, Amgen will have pivotal data on a cancer target once thought to be undruggable, and Cytokinetics will finally disclose the results of a massive study focused on heart failure.
There will also be news from Vertex Pharmaceuticals, Intercept Pharmaceuticals, and, of course, the many companies developing vaccines and therapies for Covid-19.
Read more.
As STAT’s Adam Feuerstein reports, the fourth quarter of 2020 is loaded with events that could change narratives around the industry. Beyond Biogen’s well-covered FDA panel on the Alzheimer’s disease treatment aducanumab, Amgen will have pivotal data on a cancer target once thought to be undruggable, and Cytokinetics will finally disclose the results of a massive study focused on heart failure.
There will also be news from Vertex Pharmaceuticals, Intercept Pharmaceuticals, and, of course, the many companies developing vaccines and therapies for Covid-19.
Read more.
G1, and its new CEO, are out to prove Wall Street wrong
“Short the launch” is among biotech’s oldest clichés, based on the belief that small companies are quite good at developing new medicines but more than a little lacking when it comes to actually commercializing them. G1 Therapeutics, expecting its first FDA approval in February, is changing CEOs and betting it can defy that trend.
Come Jan. 1, G1 CEO Mark Velleca will cede the reins to Jack Bailey, a pharmaceutical veteran and current board member. Velleca has led G1 since 2014, when the company, co-founded by National Cancer Institute Director Ned Sharpless, was yet to start its first clinical trial. Now G1, whose share price has fallen 55% in 2020, has the chance to prove it can market medicines as well as it develops them.
“A lot of emerging R&D companies making the transition to commercial have faltered,” Velleca said. “I think the Street tends to handicap companies in that situation. ... It’s a show-me story, and we look forward to showing.”
Read more.
Come Jan. 1, G1 CEO Mark Velleca will cede the reins to Jack Bailey, a pharmaceutical veteran and current board member. Velleca has led G1 since 2014, when the company, co-founded by National Cancer Institute Director Ned Sharpless, was yet to start its first clinical trial. Now G1, whose share price has fallen 55% in 2020, has the chance to prove it can market medicines as well as it develops them.
“A lot of emerging R&D companies making the transition to commercial have faltered,” Velleca said. “I think the Street tends to handicap companies in that situation. ... It’s a show-me story, and we look forward to showing.”
Read more.
Suddenly Trump trusts pharma?
President Trump’s tumultuous relationship with the drug industry took a turn this week after he implied that companies he once accused of “getting away with murder” now hold the keys to his re-election.
As STAT’s Matthew Herper writes, Trump, during Monday's debate with former Vice President Joe Biden, made it clear that he trusts the likes of Pfizer, Johnson & Johnson, and Moderna more than his government’s scientists when it comes to the timing of a vaccine for Covid-19.
“They can go faster than that by a lot,” Trump said after moderator Chris Wallace cited the many experts who don’t believe a vaccine will be widely available until the summer. “It’s a very political thing because people like this would rather make it political than save lives.”
It’s worth noting that the companies Trump cited have, at least publicly, said pretty much the same things about timing as the scientists he has contradicted. But Trump’s diction marks a striking departure from his usual view of the drug business, and it implies that an industry he once vilified is the only thing that can deliver the vaccine his perceived political foes want to delay.
Read more.
As STAT’s Matthew Herper writes, Trump, during Monday's debate with former Vice President Joe Biden, made it clear that he trusts the likes of Pfizer, Johnson & Johnson, and Moderna more than his government’s scientists when it comes to the timing of a vaccine for Covid-19.
“They can go faster than that by a lot,” Trump said after moderator Chris Wallace cited the many experts who don’t believe a vaccine will be widely available until the summer. “It’s a very political thing because people like this would rather make it political than save lives.”
It’s worth noting that the companies Trump cited have, at least publicly, said pretty much the same things about timing as the scientists he has contradicted. But Trump’s diction marks a striking departure from his usual view of the drug business, and it implies that an industry he once vilified is the only thing that can deliver the vaccine his perceived political foes want to delay.
Read more.
More reads
- For the first time, drug makers and PBMs must jointly face an insulin price fixing lawsuit. (STAT Plus)
- Moderna chief says its vaccine won’t be ready before the U.S. election. (Financial Times)
- China’s biotechnology boom turns suppliers into M&A targets. (South China Morning Post)
- Cancer drug bet pays off for biotech CEO with 3,600% stock surge. (Bloomberg)
.png)
No hay comentarios:
Publicar un comentario